ClinicalTrials.gg
RecruitingNCT04794075ETAPHUpdated Aug 5, 2026

Therapeutic Education and Nursing Support Program for Supportive Care, in Patients Treated With Hormone Therapy for Non-metastatic Breast Cancer

An interventional study of Therapeutic Education and Nursing Support Program for Supportive Care in Neoplasm of Breast, sponsored by Centre Hospitalier Emile Roux. Recruiting at 9 sites in France. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Centre Hospitalier Emile Roux · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,209 studies in Breast Neoplasms with a site in France — 207 open to participants now, 339 under way, 83 of them phase 3. Breast Neoplasms · France.

Planned enrollment
308th of 997
300 · median 150
Started
2021
with 75 others
No phase
339 of 1,209
73 open now
Primary completion
2028-08
later than 243 of 338 live
Registered
883rd of 1,209
by date

Among the 1,209 studies in Breast Neoplasms with a site in France, this one is the 308th largest by planned enrollment of the 997 interventional ones that give a count, is one of 76 that started in 2021, is one of 339 with no phase, reaches primary completion later than 243 of the 338 other live ones, and was the 883rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

207 of the 1,209 studies in Breast Neoplasms with a site in France are open now. Recruiting first, the newest first:

202 more — sign in →

All 207 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,209 studies in Breast Neoplasms with a site in France, or all of them as a file.
02

Study summary

To compare the efficacy of the addition of a therapeutic education program combined with nursing phone follow-up, compared to conventional management alone, on the management of adverse events (AEs) related to adjuvant hormone therapy during the first year of treatment in patients with non-metastatic breast cancer.

Read the detailed description

The main objective of the ETAPH project is to offer breast cancer patients multidisciplinary care that will limit the impact of adverse effects related to hormone therapy treatment and improve their quality of life. The achievement of this objective is based on therapeutic education and nursing follow-up throughout the first year of treatment, which, thanks to active listening and coordination of the various players, will enable global and personalized patient care.

03

Conditions studied

  • Neoplasm of Breast

Browse trials for

Keywords

  • Therapeutic Education
  • Nursing Support Program
  • Hormone Therapy
  • Non-metastatic Breast Cancer
  • Breast Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 75 years inclusive
  • Patients with non- breast cancer for whom hormone therapy (anti-oestrogen or anti-aromatase) is indicated, depending on the decision of the multidisciplinary consultation meeting.
  • Performance status () ≤ 2
  • Patient able to read and understand French (common use)
  • Patient with access to an internet connection (for collection of adverse events and responses to questionnaires on the electronic platform)
  • Patient who has been informed and has given written consent to participate in the study
  • Patient affiliated to the French social security system or equivalent

Exclusion criteria

Exclusion Criteria:

  • Patient with cancer (stage IV)
  • Patient undergoing hormone therapy
  • Patient who started hormone therapy prior to inclusion in the study
  • Patient with a history of other cancer treated by radiotherapy, chemotherapy or hormone therapy, with an end of treatment less than 2 years ago.
  • For patients in the experimental group: Inability of the patient to travel to the hospital to attend the initial assessment day and the proposed group outpatient workshops; follow-up of the program difficult for geographical, physical or other reasons (at the discretion of the investigator).
  • For patients in the control group: patients for whom telephone nursing follow-up is planned for 2 months or more or more than 4 sessions of therapeutic education.
  • Pregnant and breastfeeding women
  • Patient with a documented history of cognitive or psychiatric disorders
  • Refusal to participate, protected adult patient, under guardianship or curatorship
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Experimental group with the therapeutic education and nursing support program

    In addition to the conventional oncology follow-up, patients will participate in an initial educational assessments day.

    Other: Therapeutic Education and Nursing Support Program for Supportive Care

  • No intervention
    Control group

    Patients will have the conventional oncology follow-up.

Interventions

  • OtherTherapeutic Education and Nursing Support Program for Supportive Care

    In addition to the conventional oncology follow-up, patients will participate in an initial educational assessment day within 15 days before or after their first dose of hormone therapy. A discussion between the patient and the pivot nurse will then make it possible to define personalized objectives, thus guiding the choice of workshops in the outpatient educational program.

06

What researchers measure

Primary outcomes

  1. To compare the effectiveness of adding a therapeutic education program combined with nursing phone follow-up, compared to conventional management alone on the management of adverse events related to adjuvant hormone therapy.

    The primary endpoint is the score of the 7 adverse events (AEs), graded on a Likert scale from 0 to 4 points from the NCI-CTCAE v5.0, which will be transformed into a single composite endpoint. The 7 AEs considered here will be the most frequent and troublesome of the hormone therapy, namely: muscle and/or joint pain, hot flashes, headache, fatigue, insomnia/sleep disturbance, weight gain, nausea. This collection will be done initially (T0) and then monthly by the patients.

    Time frame: For a year

Secondary outcomes

  1. To compare the effectiveness of adding the program to conventional management alone in terms of quality of life for patients on hormone therapy at baseline (Day 0), Month 6 and Month 12.

    The score of the validated Quality of Life of Cancer Patients (EORTC-QLQ-C30) self-questionnaire score, performed at Day 0, Month 6 and Month 12 after initiation of hormone therapy

    Time frame: Change from baseline at Month 6 and Month 12

  2. To compare the effectiveness of adding the program to conventional management alone in terms of sleep quality at baseline (Day 0), Month 6 and Month 12.

    the score of the validated Pittsburgh sleep quality self-questionnaire during the past month, performed at Day 0, Month 6 and Month 12 after initiation of hormone therapy

    Time frame: Change from baseline at Month 6 and Month 12

  3. To compare the effectiveness of adding the program to conventional management alone in terms of drug use for the management of adverse events throughout the study.

    The INN name,the daily dosage and duration (number of days) of medication taken between Day 0 and 12 months, will be assessed to compare between the experimental ans the control group in term of medication use

    Time frame: From date of first Hormone Therapy intake to 12 months

  4. To compare the effectiveness of adding the program to conventional management alone in terms of therapeutic compliance at Month 6 and Month 12.

    GIRERD's subjective compliance self-questionnaire score will be filled in at Month 6 and Month 12.

    Time frame: Change from Month 6 and Month 12

  5. To compare the effectiveness of adding the program to conventional management alone in terms of patients' confidence regarding the use of hormone therapy at Day 0, Month 6 and Month 12.

    Patients' confidence in their treatment, assessed on a numerical scale from 0 to 10, measured at Day 0, Month 6 and Month 12.

    Time frame: Change from baseline at Month 6 and Month 12

  6. To compare the effectiveness of adding the program to conventional management alone in terms of patients' level of knowledge about the disease and treatment.

    Score obtained in the knowledge quizz conducted in Day 0, then at 2 months. This questionnaire is developed by our team based on Likert scales from 1 to 4.

    Time frame: Change from baseline at Month 2

  7. To compare the effectiveness of adding the program to conventional management alone in terms of patients' satisfaction with their care at Month 12.

    Score of satisfaction with patient care in relation to the needs they have had over the past 12 months. This questionnaire is developed by our team based on Likert scales from 0 to 3.

    Time frame: For a year

  8. To compare the effectiveness of adding the program to conventional management alone in terms of medico-economic impact of the program, in terms of cost-utility.

    the cost-utility ratio of the program will be calculated by estimating the costs incurred/avoided by this program and the evolution of the quality of life of the patients at different times.

    Time frame: For a year

  9. To assess patient interest in and adherence to the proposed program in the experimental group.

    Refusal rate and program participation rate The rate of premature exit or loss of sight The number and type of workshops attended by patients Evaluation of program content based on Likert scales ranging from 1 to 4.

    Time frame: For a year

  10. To describe the non-drug means used by patients to manage their adverse events and their use of supportive care during the study.

    Patients' non-drug management of side effects and use of supportive care will be recorded.

    Time frame: For a year

07

Study locations

7 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The study sponsor is the owner of the data and no use or transmission to a third party may be made without its prior consent. All information resulting from this clinical research protocol is considered confidential.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Aug 2028, 84 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 84 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2021
First posted
Mar 11, 2021
StartActual
Aug 9, 2021
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2029
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04794075
Lead sponsor
Centre Hospitalier Emile Roux
Responsible party
Sponsor
First posted
Mar 11, 2021
Start date
Aug 9, 2021
Primary completion
Aug 2028 (estimated)
Completion
Aug 2029 (estimated)
Last update
Aug 5, 2026

Study contacts

Émilie GADEA, PhD
Contact
projetetaph@ch-lepuy.fr
+33 4 71 04 35 38
Camille FARCY, PhD
Contact
camille.farcy@ch-lepuy.fr
+33 4 71 04 31 27
Séverine Breysse
principal investigator · Centre Hospitalier Emile Roux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion